Search results
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial -...
Benzinga· 6 days agoThe study did not meet the dual primary endpoints of improvement in overall survival (OS) versus...
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Zacks via Yahoo Finance· 6 days agoImage Source: Zacks Investment Research Risk Factors Lantheus’ revenues heavily depend on third...
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals
Morningstar· 6 days agoAstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals. The ...
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
Zacks via Yahoo Finance· 6 days agoAstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients...
‘A study to give us hope’: Lifestyle changes improve Alzheimer’s symptoms for some
CNN via Yahoo News· 6 days agoFollowing a vegan diet, reducing stress, exercising and sharing feelings with others helped people...
Study suggests AI may soon be able to detect cancer
Medical Xpress· 4 days agoCancer remains one of the most challenging human diseases, with over 19 million cases and 10 million deaths annually. The evolutionary nature of cancer ...
The Valley Reporter - Mad Marathon authors on the run
The Valley Reporter· 2 days agoThe 13th annual Mad Marathon features two runners who have recently published books and elite...
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Zacks· 6 days agoFree Report) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 33.3% compared with 3.1% growth of the industry. With healthy fundamentals and strong growth ...
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
Zacks via Yahoo Finance· 4 days agoThe European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for...
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Dive via Yahoo Finance· 3 days agoA medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two...